Please login to the form below

Not currently logged in
Email:
Password:

Astellas sells diabetes patents

Prosidion, a subsidiary of Astellas Pharma, has sold its patent estate relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes to Royalty Pharma for $609m

Prosidion, a subsidiary of Astellas Pharma, has sold its patent estate relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes to Royalty Pharma for $609m.

In July 2004, Prosidion acquired a portfolio of medical use patents related to the use of DPP-IV inhibitors for the treatment of type 2 diabetes. A number of non-exclusive licences to these patents have been granted to pharmaceutical companies around the world.

Royalty Pharma will be entitled to receive 100 per cent of royalty payments and milestones related to the DPP-IV asset. It will also take over administration of the DPP-IV patent estate currently owned by Prosidion.

Yoshihiko Hatanaka, president and chief executive of Astellas, said: "The sale of Prosidion's DPP-IV patent estate and royalty stream supports our strategic goal of maximising value for Astellas' shareholders. The sale of this large, passive, non-core financial asset will free up capital for reinvestment in strategic initiatives. We are pleased to have been able to work with Royalty Pharma in this important transaction."

Prosidion's assets include two drug candidates in development for diabetes and obesity, and research and development capabilities. Astellas will continue to review strategic alternatives for these assets. The range of alternatives that will be assessed could include minority investment or strategic alliance, a merger or sale of some or all of these assets.

Prosidion was acquired as part of Astellas' acquisition of OSI Pharmaceuticals in June 2010. The transaction is expected to close in July 2011.

30th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics